Church & Dwight Co., Inc. -- 5.9/10 -- $92.85
Gate result: One PARTIAL (oligopoly), two passes (FCF, management). Score normally but note the niche nature of dominant positions. CHD is a collection of #1/#2 niche brands rather than a single large-TAM franchise. The FCF profile is the strongest dimension -- record cash generation even in a weak organic growth year. Management track record is strong despite Q1 2025 miss.
| Dimension | Score | Weight | Weighted |
|---|---|---|---|
| Financial Trends | 5 | 25% | 1.25 |
| Thematic Exposure | 6.5 | 25% | 1.63 |
| Management Quality | 7.5 | 20% | 1.50 |
| Investor Sentiment | 5 | 15% | 0.75 |
| Concerns, Catalysts & Risks | 5 | 15% | 0.75 |
| Composite | 100% | 5.9 |
Church & Dwight is a $22B market cap household products company headquartered in Ewing, New Jersey, with a calendar fiscal year (December FYE). The company operates across three segments: Consumer Domestic (77% of sales), Consumer International (18%), and Specialty Products (5%). The business is built around a portfolio of #1 and #2 niche brands -- Arm & Hammer (baking soda, laundry, toothpaste), OxiClean (stain removers), Trojan (condoms), TheraBreath (oral care), Hero Cosmetics (acne patches), Batiste (dry shampoo), and Touchland (hand sanitizer, acquired July 2025).
The investment case rests on three pillars: (1) Niche oligopoly positions -- CHD holds near-monopoly share in baking soda (~90%+) and condoms (~70%+), and is #1 in acne patches, dry shampoo, and laundry sheets. These positions generate consistent pricing power and market share gains. (2) Acquisitive compounding -- the company has a proven model of identifying, acquiring, and scaling niche #1/#2 brands (TheraBreath, Hero, Touchland), funded by strong FCF ($1.1B in 2025) and a conservative balance sheet (1.5x leverage). (3) Evergreen algorithm -- management targets 4% organic growth, 50-75bps annual gross margin expansion, and 8% EPS growth, a framework that has been remarkably consistent for nearly a decade.
The concerns are growth deceleration and premium valuation. FY2025 organic growth of +0.7% was the weakest in five years, well below the 4% evergreen target. Consumer Domestic organic went negative (-0.5%) for the first time. Gross margin reversed -100bps after two years of recovery. EBITDA contracted -1.6%. Management attributes the weakness to retailer destocking, VMS drag, and consumer softness -- and the portfolio cleanup (divesting Vitamins, exiting Flawless and Showerheads) positions the go-forward business for cleaner growth. But at 24.7x forward earnings with 5-8% guided EPS growth, the stock trades at a PEG of 3-5x, requiring clean execution to hold the multiple. The 18% decline from 52-week highs has absorbed some of this concern, but the stock is not yet in deep value territory.
| Price | $92.85 | FY2025 Revenue | $6.2B (+1.6% YoY) |
| Market Cap | $22.0B | Adj EBITDA | $1,495M (-1.6% YoY) |
| Trailing P/E | 30.8x | Gross Margin | 44.7% (-100bps YoY) |
| Forward P/E | 24.7x | Adj EPS | $3.53 (+2.6% YoY) |
| 52-Week Range | $81.33 - $113.91 | Free Cash Flow | $1,083M (+10% YoY, record) |
| Dividend Yield | 1.32% | FY2025 Organic Growth | +0.7% (vs. 4% evergreen) |
CHD receives a composite score of 5.9/10, reflecting strong management quality (7.5) and solid thematic positioning (6.5), offset by weak financial trends (5), mixed sentiment (5), and balanced risk/reward (5). The FCF gate passes convincingly and management has a strong track record, but the oligopoly gate is only partial given the niche nature of dominant positions.
Bull case (~$105-115, +13-24%): 2025 was a trough year. The go-forward portfolio (ex-Vitamins, ex-Flawless) delivers 3-4% organic growth in 2026 as guided. Gross margin expands +100bps driven by portfolio mix and productivity. Touchland scales internationally and TheraBreath toothpaste launch expands oral care TAM. ARM & HAMMER marches toward $3B. EPS compounds at 8%+ and the stock re-rates toward 27-28x forward on restored algorithm credibility.
Base case (~$90-100, flat to +8%): Organic growth recovers to 2-3% but falls short of the 4% evergreen target. Gross margin improves modestly. EPS grows 5-7% aided by buybacks. New product launches (TheraBreath toothpaste, Trojan G.O.A.T.) perform in-line. Stock trades range-bound at 23-25x forward as investors wait for proof of sustained re-acceleration.
Bear case (~$75-85, -9-19%): Consumer weakness deepens, promotional spending escalates across HPC. Organic growth disappoints at 1-2% in 2026. Touchland growth slows as initial hype fades. SAP ERP transition causes execution disruption. Valuation compresses to 20-22x forward, closer to household products peer average. Stock retests $81 support.
Bottom line: CHD is a well-managed collection of niche oligopoly brands with a proven compounding model and strong cash generation. The 2025 trough was real -- organic growth collapsed and margins reversed -- but the decisive portfolio cleanup and constructive 2026 guide suggest a recovery is underway. At 24.7x forward, the stock is not cheap enough to provide a margin of safety if execution stumbles. HOLD / Watchlist, and monitor for proof that the evergreen algorithm is back on track. A clean Q1-Q2 2026 delivering 3%+ organic growth would be the catalyst to consider upgrading.
Key catalysts and monitoring points:
- Q1 2026 earnings (~May 2026): The most important near-term data point. Management guided 3-4% organic growth for the full year, with volume as the primary driver. Q1 comps are easy (-1.2% in Q1 2025), so a strong print would validate the re-acceleration thesis. Watch Consumer Domestic organic specifically -- it went negative in FY2025.
- TheraBreath toothpaste launch: Hit retail shelves in January 2026. Early online reviews strong (4.7 stars, 8 clinical studies). This is a large TAM expansion (~$4B US toothpaste category) for a brand with only 12% household penetration vs. 65% category. Track trial and repeat rates through scanner data.
- Touchland scaling: Acquired July 2025, already exceeding initial projections. Consumption growing double digits. International expansion underway (Canada, Middle East, 20-30 more countries pending regulatory clearance). Management avoiding mass channel to protect brand equity. Key question: can this become a $500M+ brand?
- Gross margin trajectory: Guided +100bps for FY2026 (above 50-75bps evergreen). Drivers include portfolio exits removing lower-margin businesses, productivity programs, and Touchland higher-margin mix. Q2 2025 trough of 43.0% should not repeat. Watch for quarterly progression back above 45%.
- ARM & HAMMER laundry share: Hit record 14.5% in FY2025, the only brand gaining share in Q4. Deep Clean innovation at 70% the price of premium competitors. Value positioning is a tailwind in the current consumer environment.
- Tariff developments: Exposure managed down from $190M to $25M through supply chain actions. CFO stated tariffs should not be a drag in 2026. But re-escalation risk remains if trade policy changes.
- SAP S/4HANA ERP go-live (2026-2027): Upgrade from existing SAP system. Management has high confidence but ERP transitions are inherently risky. Watch for any disruption signals in order fulfillment or financial reporting.
For the full analysis, see the Financials, Thematics, and Management pages.